COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
15 hedge funds and large institutions have $3.48M invested in COSCIENS Biopharma Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
50% more capital invested
Capital invested by funds: $2.31M → $3.48M (+$1.17M)
15% more funds holding
Funds holding: 13 → 15 (+2)
0.08% more ownership
Funds ownership: 0% → 0.08% (+0.08%)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
61% less call options, than puts
Call options by funds: $117K | Put options by funds: $300K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.24M |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$217K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$212K |
| 4 |
CG
Cutler Group
San Francisco,
California
|
+$70.4K |
| 5 |
Millennium Management
New York
|
+$63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$363K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$293K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$79K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$44K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$18.6K |
CSCI Hedge Fund Activity: Q4 2016 in Review
15 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q4 2016, worth a combined $3.48M — up 50% from $2.31M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CSCI positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Sabby Management, adding an estimated $1.24M. The largest seller was Renaissance Technologies, cutting an estimated $363K.
- 15 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q4 2016, up from 13 in Q3 2016.
- Funds reported $3.48M of COSCIENS Biopharma Inc. Common Stock stock for Q4 2016, up 50% quarter-over-quarter.
- 5 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q4 2016 and 3 closed out, a net change of +2 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q4 2016 was Sabby Management, an estimated $1.24M added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q4 2016 was Renaissance Technologies, an estimated $363K sold.
Based on aggregated 13F filings for Q4 2016.